IMA shares have held a relatively narrow trading range through late 2026. After closing near $4.05 in late October 2026, the stock traded near $3.92 in mid-November, a decline of approximately 3% over the trailing 30-day period. As a pre-revenue, clinical-stage biotech, the stock's price action is driven less by fundamentals than by milestones, trial updates, financing activity, and investor sentiment toward the broader OX40/OX40L antibody class, which has drawn increased attention to both efficacy and safety considerations. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
ImageneBio, Inc. is a San Diego-based clinical-stage biotechnology company developing therapeutics for immunological, autoimmune, and inflammatory diseases. Its lead program, IMG-007 (also known by its international nonproprietary name, olevaprubart), is an investigational, non-T cell-depleting, ADCC-silenced monoclonal antibody targeting OX40, a receptor found primarily on activated T cells. The molecule is engineered with a silenced antibody-dependent cell-mediated cytotoxicity function intended to avoid depleting T cells, and it features an approximately five-week half-life designed to support infrequent, convenient dosing.
The company is advancing IMG-007 in two indications. The lead program is the Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis, while a Phase 2 study in alopecia areata was planned to initiate in 2026. ImageneBio was formed in July 2025 through a reverse merger with Ikena Oncology and a concurrent $75 million private placement. The company holds worldwide commercialization rights to IMG-007, which was originally discovered by HUTCHMED. Investors follow the stock primarily for its differentiated mechanism of action within a competitive inflammatory-disease category and its potential to deliver durable responses with a low dosing burden. From what I see, the AI Pattern Search Engine highlights similar mechanisms in the sector for context.
During the trailing 30 days, the company's most consequential updates have centered on its clinical and financial progress. ImageneBio reported third-quarter 2026 financial results, continuing to fund its ongoing development programs while managing a clinical-stage cost structure. The company also presented additional data characterizing olevaprubart, including pharmacokinetic analyses supporting the loading-dose and exposure-range optimization underpinning the amended ADAPTIVE trial design.
The ADAPTIVE Phase 2b study has been expanded under a previously announced protocol amendment to evaluate four IMG-007 dosing regimens plus placebo across approximately 400 patients, systematically testing exposure, loading regimen, and dosing interval over roughly one year of continuous treatment. Management has indicated that the efficacy dataset is designed to support a potential registrational Phase 3 program. Safety remains a key area of focus for the class; as of a blinded safety review in March 2026, the company reported no cases of Kaposi sarcoma, no malignancies, and no severe infections across its clinical database.
Looking ahead, the primary catalyst for ImageneBio remains clinical execution. Investors are likely to monitor continued enrollment and progression of the amended Phase 2b ADAPTIVE trial in atopic dermatitis, as well as the initiation and early data generation from the planned Phase 2 study in alopecia areata. Topline results from ADAPTIVE are not anticipated until the fourth quarter of 2027, which means the stock's near-term narrative will depend heavily on interim updates, safety disclosures, and competitive developments across the OX40/OX40L class, where rivals are also advancing programs and where safety questions have drawn industry-wide scrutiny.
Financial durability is another key consideration. With cash, cash equivalents, and marketable securities reported at $117.2 million as of March 31, 2026, supplemented by the April 2026 private placement, management has guided to a runway into the first quarter of 2028. Regulatory developments, broader biotech sentiment, and the company's ability to preserve a differentiated safety and dosing profile will all factor into how the stock trades in the quarters ahead. As with any clinical-stage company, trial outcomes and capital needs remain the dominant drivers of risk and reward. I'm watching this closely for any interim signals that could shift sentiment.
In my own process, I frequently review Tickeron’s AI Trading Bots to scan for systematic signals across biotech names like IMA. These platforms apply pattern recognition and algorithmic analysis to thousands of tickers, helping surface data-driven ideas that complement traditional fundamental work. I find the curated trending section particularly useful for identifying strategies that align with longer-horizon clinical catalysts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The Aroon Indicator for IMA entered a downward trend on November 12, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 304 similar instances where the Aroon Indicator formed such a pattern. In 272 of the 304 cases the stock moved lower. This puts the odds of a downward move at 89%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMA as a result. In 95 of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMA's RSI Indicator exited the oversold zone, 32 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 66 cases where IMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for IMA just turned positive on November 19, 2026. Looking at past instances where IMA's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMA advanced for three days, in 172 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
IMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.331) is normal, around the industry mean (3.596). P/E Ratio (-0.876) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (35.971) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. IMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology